


Long-Term Safety of Baricitinib for RA
Upadacitinib Safety Similar to Other Jakinibs for RA

1 Step Closer: Study Examines Factors That Lead to RA in Hope of Developing Prevention Strategies

Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

For RA Patients, Functional Disability May Precede Diagnosis

Biologics May Prevent Cardiovascular Events in RA Patients

ABX464 in Phase 2a Trials for RA

Seronegative RA May Be on the Rise
- 1
- 2
- 3
- …
- 24
- Next Page »